title: Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
abstract: Eighteen patients with familial hypercholesterolemia treated with lovastatin (40 mg/day) for three months were studied to find out whether the drug induces modifications in the lipid composition of the erythrocyte membrane and whether these induce changes in the rheological behaviour of the red blood cell. Our results show that the changes observed in plasma lipids correlate with a significant decrease in the cholesterol/phospholipid ratio of the red blood cell membrane. These changes in the lipid composition of the cell are statistically related to a decrease in the erythrocyte aggregability and an improvement in blood filterability probably due to an increase in the red blood cell deformability.
authors.affiliation: Dept Biopathol Clin, Hospital Universitario La Fe, Valencia, Espana.
authors.forename: M
authors.initials: M
authors.lastname: Martinez
authors.forename: A
authors.initials: A
authors.lastname: Vaya
authors.forename: R
authors.initials: R
authors.lastname: Marti
authors.forename: L
authors.initials: L
authors.lastname: Gil
authors.forename: I
authors.initials: I
authors.lastname: Lluch
authors.forename: R
authors.initials: R
authors.lastname: Carmena
authors.forename: J
authors.initials: J
authors.lastname: Aznar
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001809:Blood Viscosity / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000187:drug effects*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D008148:Lovastatin / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008563:Membrane Lipids / Q000097:blood*; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008563:Membrane Lipids; D010743:Phospholipids; D005340:Fibrinogen; D002784:Cholesterol; D008148:Lovastatin